The View Point Medical acquisition adds a near-term catalyst in therapeutic oncology. Monitor Q2 for integration progress and any tariff-related margin commentary.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $62.01entry
- T+1 · 7mo ago 0.00%α +0.34% · $62.01
- T+5 · 6mo ago +0.52%α −1.83% · $62.33
- T+20 · 6mo ago +0.06%α −5.22% · $62.05
- T+60 · 4mo ago +26.25%α +23.18% · $78.29
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Merit Medical reported Q1 2026 EPS of $0.94 (non-GAAP, the Street convention), beating the $0.83 consensus by 13.3%, and revenue of $381.9M, exceeding the $377.6M estimate by 1.1%. The company maintained its full-year 2026 guidance for revenue of $1.612-$1.634B and non-GAAP EPS of $4.01-$4.15, while organic constant-currency revenue grew 3.7% excluding a divestiture.
Key Financial Metrics
Key Facts
- Non-GAAP EPS of $0.94 beat consensus of $0.83 by 13.3%
- Revenue of $381.9M beat consensus of $377.6M by 1.1%
- Revenue grew 7.5% YoY reported; constant-currency organic growth was 2.7% (3.7% ex-divestiture)
- Non-GAAP operating margin expanded to 19.7% from 19.3% YoY
- Free cash flow increased 26% YoY to $24.7M
- Full-year 2026 guidance maintained: revenue $1.612-$1.634B, non-GAAP EPS $4.01-$4.15
- Acquired View Point Medical on April 1, 2026 for $140M; expected to be margin-accretive
- Divested DualCap product line for $28M in February 2026
Financial Impact
EPS beat of $0.11 (13.3%) on consensus $0.83; revenue beat of $4.3M (1.1%) on consensus $377.6M
Risk Factors
- Tariff headwinds cited as incremental YoY pressure on margins
- View Point Medical acquisition expected to dilute 2026 non-GAAP EPS by ~$0.05
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285446 |
Track record
12 reports on MMSI
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +37.91% at T+60 after the May 5, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago Press Release Neutral 3/10 Entry $89.62 Now $86.35 −3.65% settles Feb 3
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $86.24 Now $86.35 +0.13% settles Jan 28
- Oct 29, 202618d ago Press Release Neutral 4/10 Entry $86.24 Now $86.35 +0.13% settles Jan 28
- Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $92.21 Now $86.35 −6.36% settles Jan 26
- Jul 2, 202619w ago Press Release Neutral 1/10 Entry $71.09 to $87.00 Now $86.35 +21.47% ▲ +22.38% +18.81% vs SPY
- May 5, 202628w ago Insider Cluster Neutral 3/10 Entry $60.44 to $83.35 Now $86.35 +42.87% ▲ +37.91% +35.17% vs SPY
- May 5, 202628w ago Insider Cluster Bullish 6/10 Entry $60.44 to $83.35 Now $86.35 +42.87% ▲ +37.91% +35.17% vs SPY
- Apr 30, 202628w ago Press Release Bullish 7/10 Viewing Entry $62.01 to $78.29 Now $86.35 +39.25% ▲ +26.25% +23.18% vs SPY
- Apr 16, 202630w ago Court Ruling Bullish 6/10 Entry $70.10 to $73.26 Now $86.35 +23.18% ▲ +4.51% −2.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers